• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Johnson & Johnson (JNJ) Stock Looks Reasonable As Crohns Drug Data Lands

    Simply Wall St·10/20/2026 14:25:57
    Listen to the news

    Johnson & Johnson has delivered a powerful multi year run in its share price, which puts a fresh spotlight on whether the current market value lines up with the cash the business is expected to generate. With recent news spanning new drug data, medtech launches and corporate reshaping plans, the question is how much of that future cash flow story is already embedded in the price.

    • Over the past 3 years, Johnson & Johnson has returned 82.6%, which raises the issue of how much of its future cash generation is already reflected in the valuation.
    • Fresh clinical results for TREMFYA in Crohn's disease and ongoing investment in medtech may support expectations for future cash inflows and help shape how durable investors think those cash flows could be.
    • If you'd rather focus on earnings, this one's for you. See why Johnson & Johnson's 38.0x P/E tells a different valuation story.

    The issue now is whether Johnson & Johnson's recent share price, after this strong multi year performance and stream of news, is justified by the cash flows implied by its intrinsic value estimate using the Discounted Cash Flow (DCF) approach.

    For context on how Johnson & Johnson's cash flow story compares across the market, compare it with companies in the 35 high quality undervalued stocks

    Does Johnson & Johnson Look Undervalued on Cash Flow?

    The Discounted Cash Flow (DCF) model here focuses on the cash Johnson & Johnson can return to shareholders over time, then compares that stream to the current $253.79 share price. Latest twelve month free cash flow sits at about $21.8b in dollar terms, and the projections reflect a growing profile, with analyst and internal estimates pointing to higher annual free cash flows into the early 2030s.

    That potential path depends on both the pharma pipeline and the medtech portfolio, so the cash story is not tied to a single product. Fresh Phase 3 data for TREMFYA in Crohn's disease, showing sustained remission outcomes, helps explain why the market may be comfortable assigning value to longer term cash generation, yet the DCF projections in this analysis still put Johnson & Johnson's estimated intrinsic value substantially above the current share price. Find out what Johnson & Johnson could be worth using our Discounted Cash Flow (DCF) estimate.

    The Johnson & Johnson Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives pick up where the Johnson & Johnson valuation puzzle leaves off by spelling out which future paths for growth, profitability and earnings would need to play out for the stock to be worth materially more or less than today’s price on the Community page. Each narrative links its figure to a clear view on how Johnson & Johnson's growth, margins and risk profile might evolve, which you can revisit as new information comes through.

    Community views on Johnson & Johnson are split between those who see more upside left in the story and those who think expectations are already well reflected.

    Bull case: 6% undervalued

    "The company's substantial investment of over $55 billion into manufacturing, R&D, and technology in the U.S. over the next four years is projected to expand capacity for advanced medicines and devices, potentially increasing operational efficiency and future earnings..."

    Discover why this Narrative puts Johnson & Johnson at 6% undervalued.

    Bear case: roughly fairly valued

    "At approximately 22 times earnings, JNJ trades near sector averages but commands a modest premium for stability, balance sheet strength, and consistent free cash flow..."

    Explore why this Narrative puts Johnson & Johnson at roughly fairly valued.

    For Johnson & Johnson, the share price is only one piece of the puzzle

    Before you make any call on Johnson & Johnson, it helps to know who is steering the business, how they are rewarded, and whether that pay structure truly lines up with your interests. See who runs Johnson & Johnson and how they are paid.